Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GERDOFF + PPI vs PPI for Extra-Esophageal GERD Symptoms
NCT03793556Completed
- Sponsor
- SOFAR
- Start
- May 2017
- Primary completion
- Sep 2018
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Randomised, open-label trial of Gerdoff in gastroesophageal reflux disease (GERD) (2 arms), sponsored by SOFAR. Primary endpoint: Change From Baseline to Visit V4 of the Total Score of RSI Questionnaire at 6 weeks. Started May 2017; status: completed.
02
Drugs
Gerdoff
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03793556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793556.